Allan Wailoo

Supporting the Era of Green Pharmaceuticals in the UK

Read more

• Health Policy and Regulation
• Innovation
• PhRMA
• Policy Analysis
• Pricing and Reimbursement
• US
• Drug Development/R&D

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

Read more

• AstraZeneca
• Innovation
• Multi-Indication Therapies
• Pricing and Reimbursement
• Combination Therapies
• Drug Development/R&D
• Health Technology Assessment…
• Precision Medicine
• Use of Medicines
• Value-Based Pricing

Payment Models for Multi-Indication Therapies

Read more

• Health Policy and Regulation
• Innovation
• PhRMA
• Policy Analysis
• US

The Lower Drug Costs Now Act and Pharmaceutical Innovation

Read more

• EFPIA
• Europe
• Health Policy and Regulation
• Healthcare Expenditure

Opportunities to Increase Efficiency in Healthcare

Read more